Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial

What Was Tested

Researchers studied Vasopressin and Desmopressin in this randomized controlled trial publication.

Eleven patients had normal dense granule stores and normal thromboxane A2 (TxA2) production (Group I), 3 patients had normal granule stores but impaired TxA2 production (Group II), and 4 had delta-storage pool deficiency (Group III).

Who Took Part

The abstract describes 18 patients taking part.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Vasopressin.

Some patients received a placebo instead of Vasopressin, giving a reference point.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Bleeding Time, Blood Coagulation Disorders, Blood Platelets, Deamino Arginine Vasopressin, Factor VIII, Hemostatics and Platelet Aggregation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in 18 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (Thrombosis and haemostasis), a journal based in Germany.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.